2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings. The author explores the data around their post-IPO share performance, relative to prior years.
2018’s Biotech IPO Bonanza: View From the After Market
